What is the treatment for a methotrexate (MTX) overdose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Methotrexate Overdose

In the event of a methotrexate overdose, early treatment with leucovorin (folinic acid) is life-saving and should be administered as promptly as possible, along with supportive measures including hydration and urinary alkalinization. 1

Initial Management

  • If the overdose occurred within 1 hour and is ≥1 mg/kg, administer activated charcoal to reduce absorption 1
  • Admit the patient to hospital immediately and measure serum methotrexate levels at least 4 hours after ingestion 1
  • Begin leucovorin (calcium folinate) administration as soon as possible - effectiveness decreases as time interval between overdose and leucovorin initiation increases 2
  • Initial leucovorin dose should be up to 100 mg/m² by intravenous infusion if methotrexate level is unknown 1
  • Continue leucovorin with subsequent oral/intravenous doses every 6 hours based on methotrexate levels 1

Supportive Care

  • Maintain aggressive hydration to improve renal elimination of methotrexate 1, 2
  • Perform urine alkalinization with sodium bicarbonate to prevent methotrexate precipitation in renal tubules 1, 2
  • Monitor complete blood count, liver function, and renal function regularly 3
  • Continue leucovorin until methotrexate levels are <0.05 μmol/L or until hematological abnormalities and mucosal ulceration have resolved 1

Management of Specific Complications

  • For bone marrow suppression: administer filgrastim (granulocyte colony-stimulating factor) subcutaneously at 5 μg/kg daily to accelerate myeloid recovery 1, 4
  • For severe cases with delayed methotrexate clearance due to renal impairment: consider glucarpidase (carboxypeptidase G2) 2, 5
    • Do not administer leucovorin within two hours before or after glucarpidase as leucovorin is a substrate for this enzyme 2
  • For intrathecal methotrexate overdose: consider CSF drainage and ventriculolumbar perfusion in addition to systemic leucovorin 2, 5

Monitoring and Follow-up

  • Monitor serum methotrexate concentration regularly to determine optimal dose and duration of leucovorin treatment 2
  • Watch carefully for signs of sepsis, which is a major cause of mortality in methotrexate overdose 2, 4
  • Monitor for mucositis, fever, diarrhea, erythema, and ulceration, which may take 6-23 days to manifest 1

Special Considerations

  • In patients with renal insufficiency, neither hemodialysis nor peritoneal dialysis significantly improves methotrexate elimination, though high-flux dialyzers may be effective 2
  • Large acute oral methotrexate poisoning (>1000 mg) should receive folinic acid therapy even with normal renal function 4
  • For intrathecal overdose, intensive systemic support with high-dose leucovorin, alkaline diuresis, and CSF drainage is required 2, 5

Common Pitfalls to Avoid

  • Do not delay leucovorin administration while waiting for methotrexate levels - early treatment is critical 1, 6
  • Do not rely solely on the folinic acid rescue therapy nomogram in acute ingestions, as it may underestimate toxicity 4
  • Avoid intrathecal administration of leucovorin as it has been associated with severe neurotoxicity and death 7
  • Do not underestimate the severity of methotrexate overdose - there is high mortality risk even with appropriate treatment 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Monitoring for Methotrexate Toxicity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pediatric case of accidental oral overdose of methotrexate.

Annals of emergency medicine, 1999

Research

Intrathecal leucovorin after intrathecal methotrexate overdose.

Journal of pediatric hematology/oncology, 1996

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.